Regramostim (GM-CSF) is a differentially glycosylated factor produced mainly by activated T cells and macrophages. Endothelial cells and fibroblasts can also produce GM-CSF after exposure to TNF-α, IL-1, IL-2 and... GM-CSF is found associated with extracellular matrix and in membrane-bound formats too.
- Mechanism
- Curator reviewed
This drug activates mononuclear phagocytes, promotes migration of epithelial cells, and further regulates cytokine production. In 2 recent placebo-controlled studies involving venous leg ulceration, subcutaneous perilesional injections of recombinant human granulocyte-macrophage colony-stimulating factor were found to be significantly better than placebo in the time to complete wound healing. In other studies, recombinant human granulocyte-macrophage colony-stimulating factor was administered topically to wounds. Several case reports have also demonstrated the use of recombinant human granulocyte-macrophage colony-stimulating factor for postsurgical wounds, chronic leg ulcers of sickle cell anemia patients, and refract and refractory pyoderma gangrenosum.
- Primary indication
- Investigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant.Curator reviewed
- Also known as
- GM-CSF (CHO cell)
- Code names
- GMC 89-107
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Regramostim, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account